viewCollagen Solutions PLC

Collagen Solutions signs new ChondroMimetic licence and distribution deal in Indonesia

Rajawali Medika will work with Collagen to obtain regulatory approval and launch ChondroMimetic in Indonesia and possibly several other South East Asian countries

knee operation
ChondroMimetic is a tissue scaffold which helps to regenerate damaged knee cartilage

Regenerative medicines group Collagen Solutions PLC (LON:COS) has signed a new licence and distribution agreement for its knee cartilage scaffold ChondroMimetic with an Indonesian partner.

Rajawali Medika will work with Collagen to obtain regulatory approval and launch ChondroMimetic in Indonesia with the potential of several other South East Asian countries.

READ: Collagen Solutions signs manufacturing agreement for Excellagen wound-healing product

Collagen said the Jakarta-based company was “highly experienced” in selling and marketing medical devices in the Asia Pacific region and has a “strong network” of orthopaedic surgeons and sales distribution channels.

“We are pleased to enter the partnership agreement with Rajawali Medika for ChondroMimetic in South East Asia,” said chief executive Jamal Rushdy.

“We will benefit enormously from both their in-depth expertise in the area of sports medicine procedures as well as their regional presence.

“This agreement adds to other distributor agreements that we have been putting in place in Asia and Europe in order to initiate our launch of ChondroMimetic soon after we obtain regulatory approval.”

ChondroMimetic is a minimally-invasive surgically placed scaffold which helps to repair knee cartilage.

Last February, results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage.

CE Mark timing ‘uncertain’

Work on a CE Mark application, which would signify that the product has passed safety, health and environmental protection requirements, began almost straight away.

Collagen had hoped to hear whether or not it had been successful by the end of March, although with the process being out of its control, it admits that the timing of any award is “uncertain”. Currently, ChondroMimetic is not approved for sale in any markets.

“We are currently awaiting feedback regarding our CE Mark submission and we will provide an update once new information becomes available and certainly no later than our proposed April trading update,” added CEO Rushdy.

Collagen Solutions shares rose 3.8% to 4.2p in late-afternoon trading on Thursday.

-- Adds share price --

Quick facts: Collagen Solutions PLC

Price: 3.25 GBX

Market: LSE
Market Cap: £14.42 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Collagen Solutions PLC named herein, including the promotion by the Company of Collagen Solutions PLC in any Content on the Site, the Company...



Collagen Solutions reports strong growth in its tissue business in first half

Collagen Solutions PLC's (LON:COS) Jamal Rushdy and Hilary Spence update Proactive London's Andrew Scott on first half performance - their third consecutive six-month period of double-digit sales growth. Revenues increased by 14% to £2.23mln in the period ended September 30. Tissue sales more...

on 3/12/19

2 min read